An Observational, Prospective Evaluation of the Trifecta™ Valve

Sponsor

Abbott Medical Devices (Industry)

Overall Status

Completed

CT.gov ID

NCT00727181

Collaborator

(none)

120

Enrollment

Locations

Arm

Duration (Months)

Patients Per Site

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This trial is designed to confirm the clinical safety and effectiveness of the Trifecta valve by establishing associated adverse event rates, clinical status as indicated by New York Heart Association (NYHA) functional classification, hemodynamic performance, and hematology analysis.

Condition or Disease	Intervention/Treatment	Phase
Aortic Valve Insufficiency Regurgitation, Aortic Valve Aortic Valve Incompetence Aortic Valve Stenosis	Device: Trifecta aortic heart valve	N/A

Detailed Description

The clinical investigation is a multi-center, multi-country, prospective, non-randomized, observational study without concurrent or matched controls, designed to evaluate the safety and effectiveness of the Trifecta valve. A maximum of 120 subjects requiring aortic valve replacement will be implanted at a maximum of 6 investigational sites in Europe. The sample size is based on late patient-years of follow-up with a minimum of 400 late patient-years experience required.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Observational, Prospective Evaluation of the Trifecta™ Valve

Study Start Date :

Nov 1, 2007

Actual Primary Completion Date :

Jul 1, 2010

Actual Study Completion Date :

Dec 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Other: Trifecta Valve The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.	Device: Trifecta aortic heart valve Replacement of a diseased, damaged, or malfunctioning aortic heart valve

Arm

Intervention/Treatment

Other: Trifecta Valve

The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.

Device: Trifecta aortic heart valve

Replacement of a diseased, damaged, or malfunctioning aortic heart valve

Outcome Measures

Primary Outcome Measures

To characterize patient NYHA functional classification status [CE labelling]
To characterize the hemodynamic performance of the valve, as per echocardiography [CE labelling]
Safety outcomes [CE labelling]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient requires aortic valve replacement. (Note: patients undergoing concomitant procedures, e.g. coronary artery bypass grafting, or valve repair, are eligible for this study).
Patient is legal age in host country.
Patient (or legal guardian) has given written informed consent for participation prior to surgery.
Patient is willing to undergo all study procedures and adhere to data collection and follow-up requirements.

Exclusion Criteria:

Patient is pregnant or nursing (women of child bearing potential must have a documented negative pregnancy test within one week prior to surgery).
Patient already has a prosthetic valve(s) at a site other than the aortic valve.
Patient requires concomitant replacement of the tricuspid, pulmonary, or mitral valve.
Patient has an inability or is unwilling to return for the required follow-up visits.
Patient has active endocarditis (patients with previous endocarditis must have two documented negative blood culture results prior to enrollment).
Patient has had an acute preoperative neurological event defined as patient has not returned to baseline or has not stabilized 30 days prior to the planned valve implantation surgery.
Patient is undergoing renal dialysis.
Patient has a documented history of substance abuse within one year of enrollment or is currently a prison inmate.
Patient is currently participating in the study of an investigational drug or device, or the patient was previously participating in an investigational drug study and has not completed a 30-day wash out period.
Patient had the Trifecta valve implanted as part of this study, but then had the device explanted.
Preoperative evaluation indicates other significant cardiovascular abnormalities such as aortic dissection or ventricular aneurysm.
Patient has a life expectancy less than two years.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Hôpital de Pontchaillou	Rennes	France	35033
2	Universitat Herzzentrum Leipzig GmbH	Leipzig	Germany	04289
3	Deutsches Herzzentrum München	München	Germany	80636
4	Onze Lieve Vrouwe Gasthuis	Amsterdam	Netherlands	1091